Reduced CNS exposure of memantine in a triple transgenic mouse model of Alzheimer's disease assessed using a novel LC-MS technique

Research output: Contribution to journalArticleResearchpeer-review

10 Citations (Scopus)

Abstract

A sensitive and robust LC-MS method for quantifying memantine (MEM) concentrations in mouse brain homogenate and perfusate was developed and validated. The developed LC-MS method exhibited good linearity between response and MEM concentrations in both perfusate and brain homogenate (r(2) = 0.98-0.99) with mean accuracy and precision values of 105.6 and 7.7 (for perfusate) and 99.0 and 9.5 (for brain homogenate). This assay was then applied to determine the impact of reported blood-brain barrier (BBB) alterations in Alzheimer s disease (AD) on the CNS exposure of the anti-AD drug, MEM. The brain uptake of MEM was measured in 12-13 and 17-19 month old wild-type (WT) and triple transgenic (3xTg) AD mice using the developed LC-MS assay and a transcardiac perfusion technique. The transcardiac perfusion technique was validated in our laboratory with marker compounds (each representing different mechanisms of transport across the BBB) to ascertain that the physical and functional properties of the BBB were maintained using this technique. While the brain uptake of MEM was not significantly different between WT and 3xTg mice at 12-13 months, MEM brain uptake was significantly (p
Original languageEnglish
Pages (from-to)198 - 206
Number of pages9
JournalJournal of Pharmaceutical and Biomedical Analysis
Volume85
DOIs
Publication statusPublished - 2013

Cite this